Drug-Resistant Melanoma Tumors Shrink When Therapy Is Interrupted, University of California, San Francisco (UCSF), Novartis Institutes for BioMedical Research, and University Hospital Zurich Study

Published: Jan 10, 2013

Researchers in California and Switzerland have discovered that melanomas that develop resistance to the anti-cancer drug vemurafenib (marketed as Zelboraf), also develop addiction to the drug, an observation that may have important implications for the lives of patients with late-stage disease.

Back to news